Company intelligence / Profile preview
Baiyiyuan BioTech
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead product (Decellularized Extracellular Matrix Implant) is in registrational clinical trials in China for facial dermal injection, has shown good preclinical safety and regeneration potential, and is expected to address market demand for long-lasting and natural medical aesthetic fillers
- Therapeutic areas
- Dermatology
- Modalities
- BiologicRecombinant proteinAlginate biomaterial
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
CMS Skinhealth (China Medical System Group Holdings' medical aesthetics subsidiary; exclusive license for marketing the Decellularized Extracellular Matrix Implant in Greater China)
Beyond the preview
Go deeper on Baiyiyuan BioTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baiyiyuan BioTech.